MediciNova Set for Breakout with Key Clinical Trials Results
AI Prediction of MediciNova, Inc. (MNOV)
MediciNova, a biopharmaceutical company focused on neurological disorders and fibrotic diseases, shows potential for significant stock movement driven by key clinical trials results for its leading drug candidates, MN-166 and MN-001. These trials are expected to provide pivotal data that could significantly impact the stock price.
MNOV Report Information
Prediction Date2025-07-03
Close @ Prediction$1.25
Mkt Cap67m
IPO DateN/a
AI-derived Information
Recent News for MNOV
- Apr 27, 7:00 pm — New Peer-Reviewed Study Reveals Actionable Immune-Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation (GlobeNewswire)
- Mar 23, 9:44 am — Super Micro downgraded, MongoDB upgraded: Wall Street's top analyst calls (The Fly)
- Mar 16, 7:00 am — MediciNova to Participate at the 38th Annual ROTH Conference (GlobeNewswire)
- Feb 20, 6:40 am — MediciNova: Q4 Earnings Snapshot (Associated Press Finance)
- Jan 29, 6:00 pm — MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients (GlobeNewswire)
- Jan 6, 9:00 am — 2026 New Year's Greetings from the CEO (GlobeNewswire)
- Dec 18, 6:00 am — MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy (GlobeNewswire)
- Dec 8, 6:00 am — MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND (GlobeNewswire)
- Dec 1, 6:00 pm — Message from the CEO to MediciNova Shareholders (GlobeNewswire)
- Nov 18, 6:00 am — MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor (GlobeNewswire)
- Nov 13, 5:22 pm — MediciNova: Q3 Earnings Snapshot (Associated Press Finance)
- Nov 7, 6:00 pm — MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards (GlobeNewswire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.